Plasma interleukin-2 levels and thyroid function in elderly patients with nonthyroidal illness

Archives of Gerontology and Geriatrics

Volumn 26, Issue 3, 1998, Pages 275-282

  Allegra, A ^a   Corica, F ^a   Buemi, M ^a   Corsonello, A ^a   Rubino, F ^a   Raffaele Addamo, F ^a   Bonanzinga, S ^a   Nicita Mauro, V ^a   Ceruso, D ^a  

^a Department of Internal Medicine   (Italy)

Author keywords

Aging; Interleukin 2; Low T3 syndrome; Nonthyroidal illness; Thyroid

Indexed keywords

INTERLEUKIN 2; LIOTHYRONINE; THYROTROPIN; THYROXINE;

AGED; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HORMONE DEFICIENCY; HUMAN; HUMAN TISSUE; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THYROID FUNCTION TEST; THYROID GLAND; THYROID HORMONE METABOLISM; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

EID: 0032079227     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4943(98)00010-7     Document Type: Article

References (23)

1. Bartalena L., Brogioni S., Grasso L., Velluzzi F., Martino E. Relationship of the increased serum interleukin-6 concentration to changes of thyroid function in nonthyroidal illness. J. Endocrinol. Invest. 17:1994;269-274.
2. Bartalena L., Brogioni S., Grasso L., Martino E. Interleukin-6 and thyroid. Eur. J. Endocrinol. 132:1995;386-393.
3. Bermudez F., Surks M.I., Oppenheimer J.H. High incidence of decreased serum triiodothyronine concentration in patients with nonthyroidal disease. J. Clin. Endocrinol. Metab. 41:1975;27-40.
4. Boelen A., Platvoet-Ter Schiphorst M.C., Wiersinga W.M. Association between serum interleukin-6 and serum 3,5,3′-triiodothyronine in nonthyroidal illness. J. Clin. Endocrinol. Metab. 77:1993;1695-1699.
5. 4 concentrations in elderly patients with non-thyroidal illness. Arch. Gerontol. Geriatr. (Suppl. 5), 451-456.
6. Dubuis I.M., Dayer J.M., Siegrist-Kaiser C.A., Burger A.G. Human recombinant interleukin 1β decreases plasma thyroid hormone and thyroid stimulating hormone levels in rats. Endocrinology. 123:1988;2175-2181.
7. Eisenstein Z., Engelsman E., Weiss M., Kalechman Y., Sredni B. Modulation of the IL-2 defect in vitro in Graves' disease. Clin. Exp. Immunol. 96:1994;323-328.
8. Komorowski J. Increased interleukin-2 level in patients with primary hypothyroidism. Clin. Immunol. Immunopathol. 63:1992;200-202.
9. Kroemer G., Francese C., Martinez C. The role of interleukin-2 in the development of autoimmune thyroiditis. Int. Rev. Immunol. 9:1992;107-123.
10. Kruit W.H., Bolhuis R.L., Goey S.H., Janser R.L., Eggermont A.M., Batchelor D., Schmitz P.I., Stoter G. Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J. Clin. Oncol. 11:1993;921-924.
11. Kung A.W., Lai C.L., Wong K.L., Tam C.F. Thyroid functions in patients treated with interleukin-2 and limphokine-activated killer cells. Q. J. Med. 82:1992;33-42.
12. Lim C.F., Bernard B.F., de Jong M., Docter R., Krenning E.P., Hennemann G. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J. Clin. Endocrinol. Metab. 76:1993;318-324.
13. Lim C.F., Docter R., Visser T.J., Krenning E.P., Bernard P., Van Toor H., de Jong M., Hennemann G. Inhibition of thyroxine transport into cultured rat hepatocytes by serum of non-uremic critically-ill patients, bilirubin and non esterified fatty acids. J. Clin. Endocrinol. Metab. 76:1993;1165-1172.
14. Mooradian A.D., Reed R.L., Osterweil D., Schiffman R., Scuderi P. Decreased serum triiodothyronine is associated with increased concentrations of tumor necrosis factor. J. Clin. Endocrinol. Metab. 71:1990;1239-1242.
15. Panciera D.L., Helfand S.C., Soergel S.A. Acute effects of continuous infusions of human recombinant interleukin-2 on serum thyroid hormone concentrations in dogs. Res. Vet. Sci. 58:1995;96-97.
16. Roger P.P., Dumont J.E. Factors controlling proliferation and differentiation of canine thyroid cells cultured in reduced serum conditions: effects of thyrotropin, cyclic AMP and growth factors. Mol. Cell. Endocrinol. 36:1984;79-93.
17. Shimonura N., Itoh M., Okugawa T., Murata T., Seo H. Effects of interleukins on EGF-stimulated growth promotion in human thyroid cells: differential modifications by IL-2 and IL-6 in Graves and normal thyroid cells. Endocr. Regul. 28:1994;55-65.
18. Tartour E., Schlumberger M., Dorval T., Baudin E., Fridman W.H. Retentissement endocrinien des immunotherapies. Ann. Endocrinol. Paris. 56:1995;143-148.
19. Van der Poll T., Romijn J.A., Wiersinga W.M., Sauerwein H.P. Tumor necrosis factor: a putative mediator of the euthyroid sick syndrome in man. J. Clin. Endocrinol. Metab. 71:1990;1567-1572.
20. Vialettes B., Guillerand M.A., Viens P., Stoppa A.M., Baume D., Sauvan R., Pasquier J., San Marco M., Olive D., Maraninchi D. Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies. Acta Endocrinol. Copenh. 129:1993;31-38.
21. Wartofsky L., Burman K.D. Alterations in thyroid function in patients with systemic illnesses: the euthyroid sick syndrome. Endocr. Rev. 3:1982;164-217.
22. Watson P.F., Pickerill A.P., Davies R., Weetman A.P. Analysis of citokine gene expression in Graves' disease and multinodular goiter. J. Clin. Endocrinol. Metab. 79:1994;355-360.
23. Weijl N., Van der Harst D., Brand A., Kooy Y., Van Luxemburg S., Schroder J., Lentjes E., Van Rood J.J., Cleton F.J., Osanto S. Hypothyroidism during immunotherapy with interleukin 2 is associated with antithyroid antibodies and response to treatment. J. Clin. Oncol. 11:1993;1376-1383.